{
    "nct_id": "NCT05052801",
    "official_title": "A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression",
    "inclusion_criteria": "* Adults with histologically documented unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer not amenable to curative therapy\n* Fibroblast growth factor receptor 2b (FGFR2b) ≥10% 2+/3+ tumor cell staining as determined by centrally performed immunohistochemistry (IHC) testing, based on tumor sample either archival (obtained within 6 months/180 days prior to signing pre-screening informed consent) or a fresh biopsy\n* Eastern Cooperative Oncology Group (ECOG) less than or equal to 1\n* Measurable disease or non-measurable, but evaluable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) V 1.1\n* Participant has no contraindications to mFOLFOX6 chemotherapy\n* Adequate organ and bone marrow function:\n\n  * absolute neutrophil count greater than or equal to 1.5 times 10^9/L\n  * platelet count greater than or equal to 100 times 10^9/L\n  * hemoglobin ≥ 9 g/dL without red blood cell (RBC) transfusion within 7 days prior to the first dose of study treatment\n  * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times the upper limit of normal (ULN) (or less than 5 times ULN if liver involvement). Total bilirubin less than 1.5 times ULN (or less than 2 times ULN if liver involvement); with the exception of participants with Gilbert's disease)\n  * calculated or measured creatinine clearance (CrCl) of ≥ 30 mL/minute calculated using the formula of Cockcroft and Gault ([140 - Age]) × Mass [kg]/[72 × Creatinine mg/dL]) (x 0.85 if female)\n  * international normalized ratio (INR) or prothrombin time (PT) less than 1.5 times ULN except for participants receiving anticoagulation, who must be on a stable dose of anticoagulant therapy for 6 weeks prior to enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Prior treatment for metastatic or unresectable disease (Note: prior adjuvant, neo-adjuvant, and peri-operative therapy is allowed if completed more than 6 months prior to first dose of study treatment)\n* Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (FGF-FGFR) pathway\n* Known human epidermal growth factor receptor 2 (HER2) positive\n* Untreated or symptomatic central nervous system (CNS) disease or brain metastases\n* Peripheral sensory neuropathy greater than or equal to Grade 2\n* Clinically significant cardiac disease\n* Other malignancy within the last 2 years (exceptions for definitively treated disease)\n* Chronic or systemic ophthalmological disorders\n* Major surgery or other investigational study within 28 days prior to first dose of study treatment\n* Palliative radiotherapy within 14 days prior to the first dose of study treatment\n* Evidence of or recent history (within 6 months) of corneal defects, corneal ulcerations, keratitis, or keratoconus, history of corneal transplant, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer.",
    "miscellaneous_criteria": ""
}